Results for tag: "Promacta"

Promacta (eltrombopag) is a hematological drug used to treat thrombocytopenia, a condition characterized by a low platelet count. It is an oral medication that works by stimulating the production of platelets in the bone marrow. Promacta is approved for use in adults and children with chronic immune thrombocytopenia (ITP) and for the treatment of thrombocytopenia in patients with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy. Promacta is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2008. It is currently marketed by Novartis, a Swiss multinational pharmaceutical company. Other companies involved in the market include GlaxoSmithKline, Shire, and Celgene. Show Less Read more